How have ATHX shares performed in 2024?

Athersys' stock was trading at $0.02 on January 1st, 2024. Since then, ATHX shares have decreased by 83.5% and is now trading at $0.0033. View the best growth stocks for 2024 here .

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.00) by $0.25. The biopharmaceutical company earned $4.79 million during the quarter. During the same quarter in the prior year, the company earned ($2.75) EPS.

When did Athersys' stock split?

Athersys shares reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com . William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Novavax (NVAX) , Rigel Pharmaceuticals (RIGL) , Vaxart (VXRT) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , T2 Biosystems (TTOO) and ADMA Biologics (ADMA) .

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATHX

Athersys (ATHX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ATHX Stock Alerts

$0.0033

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.0033
▼
$0.0048
50-Day Range: $0.0022
▼
$0.0198
52-Week Range: $0.01
▼
$1.99

Volume: 472,125 shs
Average Volume: 1.77 million shs
Market Capitalization: $203,672.70

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Athersys alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Athersys Stock (NASDAQ:ATHX)

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

ATHX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATHX Stock News Headlines

April 12, 2024 | americanbankingnews.com

Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

April 8, 2024 | bizjournals.com

Bankruptcy of once-promising Athersys winding down with assets sale

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 26, 2024 | investing.com

Toughbuilt Industries Inc (TBLT)

February 17, 2024 | morningstar.com

Athersys Inc ATHXQ

January 8, 2024 | marketwatch.com

Athersys to Sell Most Assets to Healios

November 16, 2023 | finance.yahoo.com

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

October 23, 2023 | bizjournals.com

Athersys shares migrate to Pink marketplace for broker-to-broker trading

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

October 20, 2023 | bizjournals.com

Athersys shares delisted by Nasdaq Stock Market

October 16, 2023 | finance.yahoo.com

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

October 10, 2023 | msn.com

Athersys crashes after bankruptcy warning

October 10, 2023 | finance.yahoo.com

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

October 3, 2023 | businesswire.com

Athersys Licenses its Animal Health Assets to Ardent Animal Health

October 2, 2023 | finance.yahoo.com

Athersys Director Jane Wasman Appointed Board Chair

September 26, 2023 | finance.yahoo.com

Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog

September 6, 2023 | finance.yahoo.com

Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation

August 25, 2023 | finance.yahoo.com

Is Athersys Inc (ATHX) Significantly Overvalued?

August 18, 2023 | marketwatch.com

Athersys Shares Tumble 26% After Pricing Public Offering

August 18, 2023 | investorplace.com

Why Is Athersys (ATHX) Stock Down 36% Today?

August 18, 2023 | seekingalpha.com

Athersys shares slide on pricing $3.5 million stock offering

August 18, 2023 | finance.yahoo.com

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

August 16, 2023 | finance.yahoo.com

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

August 11, 2023 | finance.yahoo.com

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

August 11, 2023 | bizjournals.com

Athersys executives foresee catalysts that could ease its financial journey

July 31, 2023 | businesswire.com

Athersys to Host Business Update Conference Call on August 9th

July 30, 2023 | fool.com

Athersys (NASDAQ: ATHX)

See More Headlines

Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATHX
CUSIP: N/A
CIK: 1368148
Web: www.athersys.com
Phone: (216) 431-9900
Fax: 216-361-9495
Employees: 24
Year Founded: 1995

Profitability

EPS (Most Recent Fiscal Year): ($2.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,530,000.00
Net Margins: N/A
Pretax Margin: -46,304.93%
Return on Equity: N/A
Return on Assets: -223.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.06
Quick Ratio: 0.06

Sales & Book Value

Annual Sales: $146,000.00
Price / Sales: 1.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.33) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 61,719,000
Free Float: 61,700,000
Market Cap: $203,672.70
Optionable: Optionable
Beta: -0.90

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Daniel A. Camardo M.B.A. (Age 54)
CEO, Secretary & Director
Comp: $796.81k
Ms. Z. Kasey Rosado (Age 49)
Interim Chief Financial Officer
Comp: $1.51M
Ms. Maia A. Hansen M.B.A. (Age 54)
M.S., Chief Operating Officer
Comp: $962.57k
Senthil Ranganathan Ph.D.
Vice President of Technical Operations
Mr. David Russ M.B.A.
Vice President of Supply Chain, Finance & Administration
Dr. Manal Morsy M.B.A.
M.D., PH.D., Executive VP & Head of Global Regulatory Affairs
Dr. Robert Mays Ph.D.
Executive VP, Head of Regenerative Medicine & Neuroscience Programs
Mr. Rakesh Ramachandran MS
Head of Information Technology & Communications and VP
Dr. Sarah Busch Ph.D.
VP of Regenerative Medicine & Head of Business Development
Ms. Ellen Gurley
Manager of Corporate Communications and Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATHX Stock Analysis - Frequently Asked Questions

How have ATHX shares performed in 2024?: Athersys' stock was trading at $0.02 on January 1st, 2024. Since then, ATHX shares have decreased by 83.5% and is now trading at $0.0033.
View the best growth stocks for 2024 here.
How were Athersys' earnings last quarter?: Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.00) by $0.25. The biopharmaceutical company earned $4.79 million during the quarter. During the same quarter in the prior year, the company earned ($2.75) EPS.
When did Athersys' stock split?: Athersys shares reverse split before market open on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What is William (B.J.) Lehmann's approval rating as Athersys' CEO?: 1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

What other stocks do shareholders of Athersys own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).
How do I buy shares of Athersys?: Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Athersys (ATHX) Stock Price, News & Analysis

About Athersys Stock (NASDAQ:ATHX)

ATHX Stock Price History

ATHX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

ATHX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info